Status:
COMPLETED
GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.
Lead Sponsor:
Antonio Di Mauro
Conditions:
Type-2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this trial was to assess glycemic control and incretin release in subjects affected by type-2 diabetes, a condition in which GLP-1 release is impaired. It is known that nutrition affects a ...
Detailed Description
Type-2 diabetes (T2D) is a multifactorial metabolic burden whose metabolic features include alterations in GLP-1 secretion and ultimately hunger/satiety circuit derangement. Manipulating the compositi...
Eligibility Criteria
Inclusion
- Type-2 diabetes history of at least 2 years, age above 18 years, body mass index (BMI) between 25 and 35 kg/m2, and drug naïve and/or with metformin treatment.
Exclusion
- clinically significant neurological, endocrinological, or other systemic diseases, as well as those with acute illness and chronic inflammatory or infective disease.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04105608
Start Date
November 1 2017
End Date
February 28 2018
Last Update
September 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Campus Bio-Medico University of Rome
Rome, Italy, 00128